Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen

MeSH terms

• Adolescent
• Antineoplastic Agents, Immunological / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
• Brentuximab Vedotin* / therapeutic use
• Child
• Doxorubicin / administration & dosage
• Doxorubicin / therapeutic use
• Female
• Hodgkin Disease* / drug therapy
• Hodgkin Disease* / pathology
• Hodgkin Disease* / therapy
• Humans
• Immunotherapy / methods
• Male
• Nivolumab* / administration & dosage
• Nivolumab* / therapeutic use
• Vinblastine / administration & dosage
• Vinblastine / therapeutic use